Celsion Announces Data Using Pulsed-High Intensity Focused Ultrasound and ThermoDox(TM) to be Presented at the 2007 Society of International Radiology Meeting.

COLUMBIA, Md. -- CELSION CORPORATION (AMEX:CLN) today reported that Dr. Sergio Dromi (Research Fellow, Diagnostic Radiology Department, NIH Clinical Center, Bethesda, MD) will present data on Pulsed-High Intensity Focused Ultrasound (HIFU) enhanced delivery of tissue levels of doxorubicin and resultant tumor growth inhibition when using heat sensitive liposomes encapsulating doxorubicin (ThermoDox). The oral presentation will be on Monday, March 5th between 8-10 a.m. at the Annual Meeting of the Society of Interventional Radiology in Seattle, WA. The study was conducted under the leadership of Dr. Steven Libutti,( )(Surgery Branch, NCI) with Dr. Brad Wood, MD and Dr. Victor Frenkel, PhD (Diagnostic Radiology Department & Molecular Imaging Laboratory, NIH Clinical Center, Bethesda, MD).

Mr. Michael Tardugno, Celsion's President of Chief Executive Officer, commented, "This study further demonstrates the ability of our heat activated liposome to deliver high levels of anticancer drugs to tumor tissue. With this HIFU based study, in addition to our on-going studies using radiofrequency ablation and microwave energy, we have further demonstrated that ThermoDox is indifferent to the heating medium triggering the drug release. We are delighted to support this exciting research under our CRADA with the NCI and the NIH Clinical Center. NIH and Celsion are collaborating on a number of pre-clinical and clinical projects. These results further underscore the utility and versatility of our platform technology. This work will be used to refine tumor targeting and ultimately to improve the efficacy of drugs using our heat activated delivery system."

About Celsion: The Prolieve Thermodilatation system is a minimally invasive transurethral microwave system which combines a transurethral microwave thermotherapy device with pressure applied by a balloon catheter.

Prolieve is marketed, in the United States, under an exclusive distribution agreement, with Boston Scientific Corporation.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.